Evaluation of the influence of various factors on progression of chronic obstructive pulmonary disease and bronchial asthma: results of long-term cohort study


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of a long-term cohort study, including 177 patients with chronic obstructive pulmonary disease (COPD) and bronchial asthma (BA). An assessment of the impact of drug and non-drug factors on the rate of progression of disorders of pulmonary ventilatory function in patients with COPD and BA over time in real clinical practice was performed. The modern statistical methods were used such as univariate and multivariate analysis of the complex of drug and non-drug effects and confounding factors. According to the results of study, the use of inhaled corticosteroids, short- and long-acting β2-agonists, short-acting anticholinergics, acetylcysteine, and antibiotics do not affect the rate of decline of forced expiratory volume in 1 second (FEV1) in patients with COPD and BA in long-term follow-up. The use of systemic glucocorticoids, bromhexine, anxiolytics, and hypnotics in patients with COPD and BA, as well as the use of ACE inhibitors in patients with BA, is associated with an acceleration of the rate of decline of FEV1. The use of statins and antacids in patients with COPD and BA, as well as use of pentoxifylline in patients with COPD correlates with the slowing rate of decline in FEV1. Information on the factors and influences that can slow down or speed up the rate of decline of lung function in patients with COPD and BA can be used in clinical practice to optimize the treatment of patients with COPD and BA with comorbidity, and objectify patient's evaluation.

Full Text

Restricted Access

About the authors

Konstantin Inalovich Tebloev

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: tebloev.k@rambler.ru
MD, professor, Head of the Department of hospital therapy №2

Kseniya Anatolievna Fomina

A.I. Yevdokimov Moscow state university of medicine and dentistry

Email: ksfomina@mail.ru
PhD, assistant of the Department of hospital therapy №2

Yevgeny Valerievich Zhilyaev

Russian medical academy of postgraduate education

MD, professor, chief doctor of the European medical center, professor of the Department of rheumatology

Andrey Aleksandrovich Spassky

N.I. Pirogov Russian national research medical university; Training center of the Russian scientific medical society of internal medicine

Email: rnmot@mail.ru
MD, professor, Department of medical pharmacology, medical faculty; Director of the Training center

References

  1. Cline M.G., Dodge R., Lebowitz M.D., Burrows B. Determinants of percent predicted FEV1 in current asthmatic subjects. Chest. 1994;106(4):1089-93.
  2. Lee J.H., Haselkorn T., Borish L., Rasouliyan L., Chipps B.E., Wenzel S.E. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest. 2007;132(6):1882-9.
  3. Tonnesen P., Carrozzi L., Fagerström K.O., Gratziou C., Jimenez-Ruiz C., Nardini S., Viegi G., Lazzaro C., Campell I.A., Dagli E., West R. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur. Respir. J. 2007;29(2):390-417.
  4. Watson L., Vonk J.M., Löfdahl C.G., Pride N.B., Pauwels R.A., Laitinen L.A., Schouten J.P., Postma D.S.; European Respiratory Society Study on chronic obstructive pulmonary disease. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the Euroscop study. Respir. Med. 2006;100(4):746-53.
  5. Schafroth T.S., Leuppi J.D. Bronchial hyper-responsiveness and exhaled nitric oxide in chronic obstructive pulmonary disease. Swiss. Med. Wkly. 2007;137(27-28):385-91.
  6. Aaron S.D., Vandemheen K.L., Fergusson D., Maltais F., Bourbeau J., Goldstein R., Balter M., O'Donnell D., McIvor A., Sharma S., Bishop G., Anthony J., Cowie R., Field S., Hirsch A., Hernandez P., Rivington R., Road J., Hoffstein V., Hodder R., Marciniuk D., McCormack D., Fox G., Cox G., Prins H.B., Ford G., Bleskie D., Doucette S., Mayers I., Chapman K., Zamel N., FitzGerald M.; Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007;146(8):545-55.
  7. Larj M.J., Bleecker E.R. Therapeutic responses in asthma and COPD. Corticosteroids. Chest. 2004;126(2):138-49.
  8. Tashkin D.P., Celli B., Senn S., Burkhart D., Kesten S., Menjoge S., Decramer M.; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008;359(15):1543-54.
  9. Douma W.R., Kerstjens H.A., de Gooijer A., Overbeek S.E., Koëter G.H., Postma D.S.; Dutch Chrionic Nonspecific Lung Disease Study Group. Initial improvements in lung function and bronchial hyperresponsiveness are maintained during 5 years of treatment with inhaled beclomethasone dipropionate and terbutaline. Chest. 2002;121(1):151-7.
  10. Chung K.F., Caramori G., Adcock I.M. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur. J. Clin. Pharmacol. 2009;65(9):853-71.
  11. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2008 г.). Под ред. А.С. Белевского. М.: Атмосфера, 2009. 100 с. [Global strategy for diagnosis, treatment and prevention of chronic obstructive pulmonary disease (2008 revision). Ed. by A.S. Belevsky. Moscow: Atmosphere, 2009. 100 p. (in Russian)]
  12. Глобальная стратегия лечения и профилактики бронхиальной астмы (пересмотр 2007 г.). Под ред. А.Г. Чучалина. М.: Атмосфера, 2008. 108 с. [Global strategy for treatment and prevention of bronchial asthma (2007 revision). Ed. by A.G. Chuchalin. Moscow: Atmosphere, 2008. 108 p. (in Russian)]
  13. Vandenbroucke J.P., von Elm E., Altman D.G., Gotzsche P.C., Mulrow C.D., Pocock S.J., Poole C., Schlesselman J.J., Egger M.; STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann. Intern. Med. 2007;147:163-94.
  14. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P.; STROBE Initiative.The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-7.
  15. Теблоев К.И., Спасский А.А., Фомина К.А., Жиляев Е.В. Факторы, влияющие на прогрессирование ХОБЛ и бронхиальной астмы. Результаты долгосрочного когортного исследования. М.: КСТ Интерфорум, 2015. 70 с. [Tebloev I.K., Spassky A.A., Fomin K.A., Zhilyaev Ye.V. Factors influencing the progression of COPD and bronchial asthma. The results of long-term cohort study. Moscow: KST Interforum, 2015. 70 p. (in Russian)]
  16. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A., Maslen T.K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297-303.
  17. Decramer M., De Benedetto F., Del Ponte A., Marinari S. Systemic effects of COPD. Respir. Med. 2005;99(Suppl. B.):3-10.
  18. Calverley P.M., Pauwels R., Vestbo J., Jones P., Pride N., Gulsvik A., Anderson J., Maden C; TRial of Inhaled STeroids ANd long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449-56.
  19. Contoli M., Baraldo S., Marku B., Casolari P., Marwick J.A., Turato G., Romagnoli M., Caramori G., Saetta M., Fabbri L.M., Papi A. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J. Allergy Clin. Immunol. 2010;125(4):830-7.
  20. Tantucci C., Modina D. Lung function decline in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2012;7:95-9.
  21. O'Byrne P.M., Pedersen S., Lamm C.J., Tan W.C., Busse W.W.; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am. J. Respir. Crit. Care Med. 2009;179(1):19-24.
  22. Jousilahti P., Vartiainen E., Tuomilehto J., Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet. 1996;348(9027):567-72.
  23. Sin D.D., Man S.F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005;2(1):8-11.
  24. Осадчук М.А., Зарубина Е.Г., Мишина Е.А. Роль эндотелиальной дисфункции в патогенезе сочетанных сердечно-легочных заболеваний. Клиническая медицина. 2006;5:31-4. [Osadchuk M.A., Zarubina Ye.G., Mishina Ye.A. The role of endothelial dysfunction in the pathogenesis of combined cardio-pulmonary diseases. Clinical medicine. 2006;5:31-4 (in Russian)]
  25. Павленко В.И. Хроническая обструктивная болезнь легких сочетанная с ишемической болезнью сердца: клинико-функциональные особенности течения, механизмы взаимоотягощения, диагностика, прогнозирование и лечение. Автореферат дисс.. д-ра мед. наук. Благовещенск, 2012. 43 с. [Pavlenko V.I. Chronic obstructive pulmonary disease combined with ischemic heart disease: clinical-functional peculiarities of mechanisms of mutual burdening, diagnosis, prognosis and treatment. The author's abstract of dissertation for the MD degree. Blagoveshchensk, 2012. 43 p.(in Russian)]
  26. Gayan-Ramirez G., Decramer M. The effect of corticotherapy on respiratory muscles. Rev. Mal. Respir. 1998;15(1):33-41.
  27. Global strategy for asthma management and prevention (reviced 2014): Global Initiative For Asthma (GINA). URL: http://www. ginasthma.org. 2014. p. 132.
  28. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2014): Global Initiative For Chronic Obstructive Lung Disease (GOLD). URL: http://www.goldcopd.org. 2014. p. 84.
  29. Клячкина И.Л. Муколитические препараты при продуктивном кашле у больных хронической обструктивной болезнью легких. Consilium Medicum. 2007;9(3):58-62. [Klyachkina I.L. Mucolytic drugs for productive cough in patients with chronic obstructive pulmonary disease. Consilium Medicum. 2007;9(3):58-62 (in Russian)]
  30. Чазова И.Е., Чучалин А.Г., Зыков К.А., Ратова Л.Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктвиной болезнью легких. Рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества. Системные гипертнезии. 2013;1:5-34. [Chazova I.Ye., Chuchalin A.G., Zykov K.A., Ratova L.G. Diagnosis and treatment of patients with arterial hypertension and chronic obstructive lung disease. Recommendations of Russian medical society on arterial hypertension and Russian respiratory society. System hypertensions. 2013;1:5-34 (in Russian)]
  31. Задионченко В.С., Шехян Г.Г., Быльева А.А., Щикота A.M., Ялымов A.A. Особенности гиполипидемического и некоторых плейотропных эффектов симвастатина. Русский медицинский журнал. 2010;18(10):691 -6. [Zadionchenko V.S., Shekhyan G.G., Byl'eva A.A., Shchikota A.M., Yalymov A.A. Features of lipid-lowering and pleiotropic effects of simvastatin. Russian medical journal. 2010;18(10):691-6 (in Russian)]
  32. Маев И.В., Самсонов А.А., Голубев Н.Н. Препараты висмута в лечении больных язвенной болезнью желудка и двенадцатиперстной кишки. Клиническая медицина. 2008;86(9):57-63. [Maev I.V., Samsonov A.A., Golubev N.N. Bismuth preparations in the treatment of patients with peptic ulcer of stomach and duodenum. Clinical medicine. 2008;86(9):57-63 (in Russian)]
  33. Jiang S.P., Huang L.W. Role of gastroesophageal reflux disease in asthmatic patients. Eur. Rev. Med. Pharmacol. Sci. 2005;9(3):151-60.
  34. Larsen J., Arnberg A., Brosen K. Tramadol and oxazepam. Effect on pulmonry function in elderly patients with chronic obstructive lung disease. Ugeskr. Laeger. 2001;163(4):458-60.
  35. Samlaska C.P., Winfield E.A. Pentoxifylline. J. Am. Acad. Dermatol. 1994;30(4):603-21.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies